Faster, More Frequent An Australian Biotech’s New Approach to Radiopharmaceutical Cancer Treatment

An Australian biotechnology company has filed a patent for a new dosing strategy for targeted radiopharmaceutical cancer treatments – one that takes advantage of short-lived radioisotopes with half-lives of less than 24 hours to deliver more frequent, lower-toxicity doses to cancer patients. The approach could make this cutting-edge cancer treatment more accessible and effective, particularly for patients with limited life expectancy.

The Problem

Targeted radiopharmaceuticals represent one of the most exciting frontiers in cancer treatment. These precision medicines combine a molecule that homes in on cancer cells with a radioactive payload, delivering a lethal dose of radiation directly to tumours while largely sparing healthy tissue. Currently, the most widely used radiopharmaceuticals – those based on iodine-131, yttrium-90 or lutetium-177 – have relatively long radioactive half-lives of around 8, 2.7 and 6.7 days respectively.

Because these isotopes remain active in the body for extended periods, patients typically receive only 4 to 6 doses over a full treatment course, with each administration spaced 6 to 8 weeks apart. This cautious approach is necessary to avoid cumulative toxicity and to allow clinicians time to monitor the patient for side effects. For patients in good health with years ahead of them, this schedule is manageable. But for patients with advanced cancer and a prognosis of less than 12 months, a treatment course stretching over 9 months or more may simply take too long to deliver meaningful benefit.

Short-lived radioisotopes – those with half-lives of under 24 hours – offer an intriguing alternative. They clear from the body quickly, potentially reducing systemic toxicity. But conventional dosing regimes were never designed around them, leaving their therapeutic potential largely unexplored in structured clinical settings.

What This Invention Does

AdvanCell‘s invention describes a new treatment protocol specifically designed for short-lived radioisotopes. Rather than administering a handful of large doses weeks apart, the method involves giving patients two or more separate doses within a dosing interval of approximately 4 weeks or less. Because the radioisotope clears the body so quickly, patients can receive more frequent treatment without the same toxicity concerns that constrain longer-lived isotopes.

This more frequent dosing approach could allow clinicians to maintain a more consistent level of therapeutic radiation at the tumour site over the course of treatment, potentially improving efficacy while compressing the overall treatment timeline. For patients with aggressive cancers and limited time, completing an effective course of treatment in weeks rather than months could be the difference between a treatment that works and one that runs out of time.

The patent also covers the formulation of the radiopharmaceutical itself – including injectable solutions and the choice of carrier molecules – providing a comprehensive framework for clinical implementation.

Key Features

Short half-life radioisotope focus. The invention specifically targets radioisotopes with half-lives of less than approximately 24 hours, a class of agents that clears the body rapidly and thus enables fundamentally different dosing strategies compared to conventional radiopharmaceuticals.

Compressed dosing intervals. By scheduling two or more doses within a 4-week window, the protocol delivers more frequent therapeutic radiation while managing systemic exposure – a significant departure from the 6 to 8-week spacing used with longer-lived isotopes.

Reduced toxicity window. The rapid clearance of short-lived radioisotopes means each dose poses a shorter window of systemic radiation exposure, potentially reducing side effects and expanding the patient population that can safely receive treatment.

Flexible formulation coverage. The patent covers injectable solution formulations including the use of carrier and targeting molecules (classified under A61K 47/16 and A61K 47/64), giving the invention scope across a range of specific radiopharmaceutical products.

Benefit for patients with limited prognosis. The compressed treatment schedule is particularly relevant for patients with short life expectancies, for whom a conventional 9-month treatment course would be impractical or impossible to complete.

Who Is Behind It?

AdvanCell Pty Limited is an Australian biotechnology company focused on the development of targeted radiopharmaceutical therapies for cancer. The Australian priority application (AU 2023902414) was filed on 31 July 2023, with the international PCT application (PCT/AU2024/050810) filed in July 2024. The current application is a divisional of AU 2024317034. The inventors are Andrew Adamovich, Simon Puttick, Thomas Kryza, Feifei Liu and Stephen Rose. The application is managed by FB Rice Pty Ltd in Sydney.

Why It Matters

Targeted radiopharmaceuticals are one of the fastest-growing areas in oncology, with a number of approved treatments and a large pipeline of new agents in clinical development. The global market is expanding rapidly as the advantages of precision radiation delivery over conventional chemotherapy and external beam radiotherapy become increasingly clear.

AdvanCell’s innovation is particularly timely given growing interest in alpha-emitting and other short-lived radioisotopes that are difficult to use under conventional dosing frameworks. By establishing a new clinical protocol specifically optimised for short-lived agents, this patent could unlock a new generation of treatments that are not just more effective but also more humane – shortening the ordeal of cancer treatment for patients who may have very little time to spare. With IPC classifications covering radiopharmaceutical formulations (A61K 51/08) and antineoplastic therapy (A61P 35/00), the patent spans both formulation chemistry and clinical application.

---

AU 2026201506 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Peptide receptor radionuclide therapy (PRRT) is the best-established form of targeted radiopharmaceutical treatment, using radiolabelled peptides to deliver lethal radiation directly to tumour cells. Targeted alpha therapy is an emerging variant that uses alpha-emitting isotopes for even more localised, high-energy cell killing, with short-lived isotopes like lead-212 offering rapid clearance that may enable the more frequent dosing schedules described in AdvanCell‘s patent.